Reata Pharmaceuticals (RETA) PT Lowered to $110 at Baird, Following Clinical Business Update
Tweet Send to a Friend
Baird analyst Brian Skorney lowered ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
